{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:49:36Z","timestamp":1790984976362,"version":"4.1.0"},"reference-count":111,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,1,12]],"date-time":"2006-01-12T00:00:00Z","timestamp":1137024000000},"content-version":"vor","delay-in-days":407,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of the New York Academy of Sciences"],"published-print":{"date-parts":[[2004,12]]},"abstract":"<jats:p><jats:bold>A<jats:sc>bstract<\/jats:sc>: <\/jats:bold> Several neurodegenerative disorders, such as multiple sclerosis, Alzheimer's disease, and Parkinson's disease, are associated with inflammatory damage. The complex process of neuroinflammation involves various components of the immune system and the central nervous system. Particularly, brain astrocytes and microglial cells generate several inflammatory mediators like cytokines, leukotrienes, superoxide radicals, eicasonoids, and the components of the complement cascade. Complement plays an important role in the etiology of most of the neuroinflammatory disorders. To prevent long\u2010term dysfunction inflammation in the central nervous system must be modulated with neuroprotective agents such as nonsteroidal anti\u2010inflammatory drugs, steroids, phenolic thiazoles, nitrones, catechins, nitric oxide synthetase inhibitors, flavonoids, and phosphodiesterase inhibitors. Few drugs are found to be effective and their therapeutic benefit is hampered by side effects. Most of the neuroprotective agents are free radical scavengers and many inhibit only one or two aspects of inflammation. The complement inhibitory activity of most of these agents is either unknown or not established. Thus, there is doubt regarding their therapeutic value in most of the inflammatory disorders in which complement plays a major role. In this context the role of a multifunctional protein, vaccinia virus complement control protein (VCP), is quite significant as it may play a pivotal role in the treatment of several neuroinflammatory disorders. VCP is known to inhibit both complement pathways involved in inflammation. It is also known to inhibit cytokines and chemokines in inflammation. Our recent studies on rats demonstrate that VCP administration inhibits macrophage infiltration, reduces spinal cord destruction, and improves motor skills associated with spinal cord injury, establishing VCP as a strong candidate for neuroprotection. Thus, complement inhibitors such as VCP can serve as neuroprotective agents in inflammation associated with several neurodegenerative disorders.<\/jats:p>","DOI":"10.1196\/annals.1332.010","type":"journal-article","created":{"date-parts":[[2005,1,29]],"date-time":"2005-01-29T01:15:36Z","timestamp":1106961336000},"page":"147-164","source":"Crossref","is-referenced-by-count":34,"title":["Neuroprotection from Complement\u2010Mediated Inflammatory Damage"],"prefix":"10.1111","volume":"1035","author":[{"given":"AMOD P.","family":"KULKARNI","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LAURIE A.","family":"KELLAWAY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DEBOMOY K.","family":"LAHIRI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GIRISH J.","family":"KOTWAL","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,1,12]]},"reference":[{"key":"e_1_2_11_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0197-4580(98)00100-6"},{"key":"e_1_2_11_3_2","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.parkreldis.2004.01.005","article-title":"Inflammation and neurodegeneration in Parkinson's disease","volume":"10","author":"McGeer P.L.","year":"2004","journal-title":"Parkinson Rel. Disorders"},{"key":"e_1_2_11_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.10146"},{"key":"e_1_2_11_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10481"},{"key":"e_1_2_11_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.10.1364"},{"key":"e_1_2_11_7_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-003-0768-0"},{"key":"e_1_2_11_8_2","doi-asserted-by":"crossref","unstructured":"Reynolds D.N.et al.2003. Vaccinia virus complement control protein reduces neutrophil infiltration following spinal cord injury. Ann. N.Y. Acad. Sci.1010:534\u2010 539.","DOI":"10.1196\/annals.1299.099"},{"key":"e_1_2_11_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.21.2819"},{"key":"e_1_2_11_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.53.1.197"},{"key":"e_1_2_11_11_2","first-page":"S1","article-title":"Glial cell reactions in neurodegenerative diseases: pathophysiology and therapeutic interventions","volume":"2","author":"McGeer P.L.","year":"1998","journal-title":"Alzh. Dis. Assoc. Disord."},{"key":"e_1_2_11_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/glia.440070114"},{"key":"e_1_2_11_13_2","doi-asserted-by":"publisher","DOI":"10.1006\/exnr.1999.7170"},{"key":"e_1_2_11_14_2","first-page":"4726","article-title":"Complement expression in human brain","volume":"154","author":"Gasque P.","year":"1995","journal-title":"Biosynthesis of terminal pathway components and regulators in human glial cells and cell lines. J. Immunol."},{"key":"e_1_2_11_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(98)01390-3"},{"key":"e_1_2_11_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(01)02003-0"},{"key":"e_1_2_11_17_2","first-page":"6551","volume":"163","author":"Davoust N.","year":"1999","journal-title":"Central nervous system\u2014targeted expression of the complement inhibitor sCrry prevents experimental allergic encephalomyelitis"},{"key":"e_1_2_11_18_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.166.6.4154"},{"key":"e_1_2_11_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-2236(96)10049-7"},{"key":"e_1_2_11_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3959(00)00490-5"},{"key":"e_1_2_11_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200107030-00034"},{"key":"e_1_2_11_22_2","first-page":"375","article-title":"Glutamate excitotoxicity\u2014a mechanism for axonal damage and oligodendrocyte death in multiple sclerosis? J","volume":"60","author":"Werner P.","year":"2000","journal-title":"Neural Transm. Suppl."},{"key":"e_1_2_11_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.05.001"},{"key":"e_1_2_11_24_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3276004"},{"key":"e_1_2_11_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101031200"},{"key":"e_1_2_11_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01191555"},{"key":"e_1_2_11_27_2","first-page":"399","article-title":"Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease","volume":"148","author":"Christie R.H.","year":"1996","journal-title":"Am. J. Pathol."},{"key":"e_1_2_11_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(99)00007-8"},{"key":"e_1_2_11_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64604-4"},{"key":"e_1_2_11_30_2","doi-asserted-by":"publisher","DOI":"10.1385\/MN:25:1:001"},{"key":"e_1_2_11_31_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0901-04.2004"},{"key":"e_1_2_11_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(01)01842-0"},{"key":"e_1_2_11_33_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.2000.0380"},{"key":"e_1_2_11_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.03.012"},{"key":"e_1_2_11_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb03138.x"},{"key":"e_1_2_11_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0167-5699(96)20028-F"},{"key":"e_1_2_11_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2003.08.001"},{"key":"e_1_2_11_38_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.2852"},{"key":"e_1_2_11_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-5890(97)00005-9"},{"key":"e_1_2_11_40_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.57.070188.001541"},{"key":"e_1_2_11_41_2","doi-asserted-by":"publisher","DOI":"10.1006\/nbdi.1996.0020"},{"key":"e_1_2_11_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(99)00261-1"},{"key":"e_1_2_11_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2001.00167.x"},{"key":"e_1_2_11_44_2","first-page":"1","article-title":"The role of neuroinflammation and neuroimmune activation in persistent pain","volume":"90","author":"Osaka H.","year":"1999","journal-title":"Pain"},{"key":"e_1_2_11_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001756-200102120-00022"},{"key":"e_1_2_11_46_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.12.040194.004015"},{"key":"e_1_2_11_47_2","first-page":"1003","article-title":"C3a\u2010induced contraction of guinea pig ileum consists of two components: fast histamine\u2010mediated and slow prostanoid\u2010mediated","volume":"248","author":"Balzo U.","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_11_48_2","first-page":"432","article-title":"Conformationally biased analogs of human C5a mediate changes in vascular permeability","volume":"278","author":"Kawatsu R.","year":"1996","journal-title":"Pharmacol Exp. Ther."},{"key":"e_1_2_11_49_2","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.4049\/jimmunol.160.7.3543","article-title":"The receptor for complement anaphylatoxin c3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis","volume":"160","author":"Gasque P.","year":"1998","journal-title":"J. Immunol."},{"key":"e_1_2_11_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04077.x"},{"key":"e_1_2_11_51_2","doi-asserted-by":"publisher","DOI":"10.1385\/MN:27:3:325"},{"key":"e_1_2_11_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(02)00506-7"},{"key":"e_1_2_11_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2003.09.008"},{"key":"e_1_2_11_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(02)03979-3"},{"key":"e_1_2_11_55_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.1999.00764.x"},{"key":"e_1_2_11_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10261"},{"key":"e_1_2_11_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2003.11.031"},{"key":"e_1_2_11_58_2","doi-asserted-by":"publisher","DOI":"10.1179\/016164104225016236"},{"key":"e_1_2_11_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2003.10.041"},{"key":"e_1_2_11_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2003.11.007"},{"key":"e_1_2_11_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/ar70"},{"key":"e_1_2_11_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70129-6"},{"key":"e_1_2_11_63_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1999.0722426.x"},{"key":"e_1_2_11_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.10681"},{"key":"e_1_2_11_65_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:NERE.0000014822.69384.0f"},{"key":"e_1_2_11_66_2","doi-asserted-by":"crossref","first-page":"6896","DOI":"10.4049\/jimmunol.161.12.6896","article-title":"Astrocyte\u2010derived monocyte\u2010chemoattractant protein\u20101 directs the transmigration of leukocytes across a model of the human blood\u2010brain barrier","volume":"161","author":"Weiss J.M.","year":"1998","journal-title":"J. Immunol."},{"key":"e_1_2_11_67_2","doi-asserted-by":"crossref","first-page":"7505","DOI":"10.1523\/JNEUROSCI.20-20-07505.2000","article-title":"Deficiency of complement defense protein CD59 may contribute to neurodegeneration in Alzheimer's disease","volume":"20","author":"Yang L.B.","year":"2000","journal-title":"J. Neurosci."},{"key":"e_1_2_11_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1385-299X(96)00026-8"},{"key":"e_1_2_11_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2003.02230.x"},{"key":"e_1_2_11_70_2","doi-asserted-by":"publisher","DOI":"10.2174\/1389450033346957"},{"key":"e_1_2_11_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2003.09.004"},{"key":"e_1_2_11_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-5846(03)00124-6"},{"key":"e_1_2_11_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0169-328X(00)00149-2"},{"key":"e_1_2_11_74_2","first-page":"81","article-title":"Role of cytokines in the gene expression of amyloid \u03b2\u2010protein precursor: identification of a 5\u2032\u2010UTR\u2010binding nuclear factor and its implications in Alzheimer's disease","volume":"5","author":"Lahiri D.K.","year":"2003","journal-title":"J. Alz. Dis."},{"key":"e_1_2_11_75_2","first-page":"252","article-title":"Complement association with neurons and \u03b2\u2010amyloid deposition in the brains of aged individuals with Down syndrome Neurobiol","volume":"8","author":"Head E.","year":"2001","journal-title":"Dis."},{"key":"e_1_2_11_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(98)00086-0"},{"key":"e_1_2_11_77_2","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.4049\/jimmunol.136.12.4456","article-title":"Activated terminal complement in cerebrospinal fluid in Guillain\u2010Barre syndrome and multiple sclerosis","volume":"136","author":"Sanders M.E.","year":"1986","journal-title":"J. Immunol."},{"key":"e_1_2_11_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(99)00328-7"},{"key":"e_1_2_11_79_2","first-page":"83","article-title":"Inflammation in Parkinson's disease","volume":"86","author":"McGeer P.L.","year":"2001","journal-title":"Adv. Neurol."},{"key":"e_1_2_11_80_2","doi-asserted-by":"publisher","DOI":"10.1089\/089771504774129937"},{"key":"e_1_2_11_81_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-03-00955.2003"},{"key":"e_1_2_11_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2003.09.010"},{"key":"e_1_2_11_83_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199605000-00010"},{"key":"e_1_2_11_84_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(03)00881-4"},{"key":"e_1_2_11_85_2","doi-asserted-by":"publisher","DOI":"10.1080\/15216540310001628717"},{"key":"e_1_2_11_86_2","first-page":"1","article-title":"Neuroinflammation, COX\u20102, and ALS\u2014a dual role? Exp","volume":"187","author":"Consilvio C.","year":"2004","journal-title":"Neurol."},{"key":"e_1_2_11_87_2","first-page":"59","article-title":"Therapeutic inhibition of the complement system","volume":"50","author":"Makrides S.C.","year":"1998","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_11_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.devbrainres.2004.03.006"},{"key":"e_1_2_11_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-0760(02)00262-5"},{"key":"e_1_2_11_90_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.10.7693"},{"key":"e_1_2_11_91_2","first-page":"1067","article-title":"A randomized controlled trial of prednisone in Alzheimer's disease","volume":"55","author":"Aisen P.S.","year":"2000","journal-title":"Alzheimer's disease cooperative study. Neurology 54: 588\u2013593; Comment Neurology"},{"key":"e_1_2_11_92_2","unstructured":"Reichman W.E. 2000. Alzheimer's disease: clinical treatment options. Am. J. Manag. Care6:S1125\u2010S1132 [discussion: S1133\u2010S1138]."},{"key":"e_1_2_11_93_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2003.08.063"},{"key":"e_1_2_11_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb02103.x"},{"key":"e_1_2_11_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2003.09.009"},{"key":"e_1_2_11_96_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2003.09.077"},{"key":"e_1_2_11_97_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.115"},{"key":"e_1_2_11_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2004.03.002"},{"key":"e_1_2_11_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(03)02296-0"},{"key":"e_1_2_11_100_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2004.02.043"},{"key":"e_1_2_11_101_2","first-page":"10837","volume":"99","author":"Wyss\u2010Coray T.","year":"2002","journal-title":"Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice"},{"key":"e_1_2_11_102_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63744-3"},{"key":"e_1_2_11_103_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02970146"},{"key":"e_1_2_11_104_2","doi-asserted-by":"publisher","DOI":"10.1038\/335176a0"},{"key":"e_1_2_11_105_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2237434"},{"key":"e_1_2_11_106_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/166.6.1245"},{"key":"e_1_2_11_107_2","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.4049\/jimmunol.160.11.5596","article-title":"Interaction of vaccinia virus complement control protein with human complement proteins: factor I\u2010mediated degradation of C3b to iC3b1 inactivates the alternative complement pathway","volume":"160","author":"Sahu A.","year":"1998","journal-title":"J. Immunol."},{"key":"e_1_2_11_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-5728(00)00183-1"},{"key":"e_1_2_11_109_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200103270-00019"},{"key":"e_1_2_11_110_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2002.tb04659.x"},{"key":"e_1_2_11_111_2","doi-asserted-by":"publisher","DOI":"10.1089\/08977150260139093"},{"key":"e_1_2_11_112_2","first-page":"242","article-title":"Poxviral mimicry of complement and chemokine system components: what's the end game? Immunol","volume":"21","author":"Kotwal G.J.","year":"2000","journal-title":"Today"}],"container-title":["Annals of the New York Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1196%2Fannals.1332.010","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1196\/annals.1332.010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T20:03:50Z","timestamp":1695672230000},"score":1,"resource":{"primary":{"URL":"https:\/\/nyaspubs.onlinelibrary.wiley.com\/doi\/10.1196\/annals.1332.010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,12]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,12]]}},"alternative-id":["10.1196\/annals.1332.010"],"URL":"https:\/\/doi.org\/10.1196\/annals.1332.010","archive":["Portico"],"relation":{},"ISSN":["0077-8923","1749-6632"],"issn-type":[{"value":"0077-8923","type":"print"},{"value":"1749-6632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,12]]}}}